Citi Initiates Coverage on Isis Pharmaceuticals (ISIS) with a Hold, May Become Core Biotech Holding When Profitable
Tweet Send to a Friend
Citi initiates coverage on Isis Pharmaceuticals (Nasdaq: ISIS) with a Hold. Price target $16.
Citi analyst says, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Citi analyst says, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
